U.S. markets close in 1 minute
  • S&P 500

    3,367.09
    +31.62 (+0.95%)
     
  • Dow 30

    27,819.64
    +366.98 (+1.34%)
     
  • Nasdaq

    11,177.94
    +92.69 (+0.84%)
     
  • Russell 2000

    1,504.68
    -0.05 (-0.00%)
     
  • Crude Oil

    40.02
    +0.73 (+1.86%)
     
  • Gold

    1,893.20
    -10.00 (-0.53%)
     
  • Silver

    23.44
    -1.00 (-4.11%)
     
  • EUR/USD

    1.1729
    -0.0017 (-0.14%)
     
  • 10-Yr Bond

    0.6770
    +0.0320 (+4.96%)
     
  • GBP/USD

    1.2910
    +0.0050 (+0.39%)
     
  • USD/JPY

    105.4840
    -0.1710 (-0.16%)
     
  • BTC-USD

    10,740.42
    -103.79 (-0.96%)
     
  • CMC Crypto 200

    221.26
    -0.13 (-0.06%)
     
  • FTSE 100

    5,866.10
    -31.40 (-0.53%)
     
  • Nikkei 225

    23,185.12
    -353.98 (-1.50%)
     

Integer Holdings Corporation Reports First Quarter 2020 Results

~ Strong Earnings Per Share growth: +45% GAAP, +25% adjusted ~
~ Suspending 2020 guidance given COVID-19 uncertainty ~

PLANO, Texas, May 07, 2020 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (ITGR), a leading medical device outsource manufacturer, today announced results for the three months ended April 3, 2020.  Unless otherwise stated, all results and comparisons are from continuing operations.

Responding to the challenges of the COVID-19 pandemic

  • Integer is prioritizing the safety of its associates while providing critical products that its customers and patients rely on every day; as an essential business, all of Integer’s manufacturing sites are operating with social distancing and enhanced cleaning protocols.

  • Integer is communicating closely with its customers and suppliers to meet product demand and responding to increased critical needs, such as ventilator and patient monitoring components.

  • First quarter sales were largely unaffected by COVID-19 and operational inefficiencies related to COVID-19 were more than offset by strong operating income growth.

  • Integer is suspending its previously announced annual guidance for 2020, due to the uncertainty of the impact and the recovery period of the COVID-19 pandemic.  We expect the pandemic to temporarily reduce sales and profits.

  • Early in the second quarter, Integer executed a draw down of our full revolver to protect against the possibility of a prolonged pandemic coupled with financial market illiquidity.

  • As the sales reduction is expected to be temporary, we are taking a balanced approach to managing costs and protecting critical investments to be stronger post COVID-19.

First Quarter 2020 Highlights (compared to First Quarter 2019)

  • Sales increased $14 million to $328 million, an increase of 4%.

  • GAAP income increased $10 million to $31 million, an increase of 46%.  Non-GAAP adjusted income increased $8 million to $41 million, an increase of 26%.

  • Adjusted EBITDA increased $5 million to $71 million, an increase of 8%.

  • GAAP diluted EPS increased $0.29 per share to $0.94 per share, an increase of 45%.  Non-GAAP adjusted diluted EPS increased $0.25 per share to $1.25 per share, an increase of 25%.

  • Net total debt decreased $8 million from the end of 2019 to $804 million, achieving a leverage ratio of 2.8 times adjusted EBITDA.

“I’d like to recognize and thank all of our associates that remain committed to supplying critical components and products on which patients depend,” said Joseph Dziedzic, Integer’s president and chief executive officer. “We are taking the necessary actions in our manufacturing sites to protect our associates and continue operations. Our strong first quarter results were largely unaffected by COVID-19 and we are working closely with our customers and suppliers to manage changes in demand.  Given the COVID-19 uncertainty we are suspending 2020 guidance and we executed a revolver draw down to protect against a prolonged pandemic coupled with financial market illiquidity. As the sales reduction is expected to be temporary, we are taking a balanced approach to managing costs and protecting critical investments to be stronger post COVID-19.”

Discussion of Product Line First Quarter 2020 Sales (compared to First Quarter 2019)

  • Cardio & Vascular sales increased 17% driven by a strong increase in peripheral vascular demand from a customer’s continued launch of an existing program into a new geography.  We saw strong overall growth across most markets.  The quarter also benefited from incremental sales from the start of a new customer contract on existing business.  The impact of COVID-19 was negligible in the first quarter.

  • Cardiac & Neuromodulation sales decreased 8%. Neuromodulation declined from Nuvectra’s bankruptcy ($6 million) and headwind from 2019 supply agreement commitments.  Strong CRM growth from product launches and increased battery demand was partially offset by prior year impact of signing of a customer contract on existing business.   The impact of COVID-19 was negligible in the first quarter.

  • Advanced Surgical, Orthopedics & Portable Medical includes sales to the acquirer of our AS&O product line, Viant, under supply agreements entered into as part of the divestiture. Sales declined 1% driven by a decrease in Portable Medical battery demand, offset by increased end-market demand for Advanced Surgical and Orthopedic base products.  The impact of COVID-19 was negligible in the first quarter.

  • Electrochem sales declined 25% driven by a severe decline in the energy market due to both oversupply and demand fall-out from COVID-19 pandemic.

 

 

Summary of Financial and Product Line Results from Continuing Operations

 

 

 

(dollars in thousands, except per share data)

Three Months Ended

GAAP

April 3,
2020

 

March 29,
2019

 

Change

 

Organic
Growth(a)

Medical Sales

 

 

 

 

 

 

 

Cardio & Vascular

$

179,205

 

$

152,574

 

17.5

%

 

16.8

%

Cardiac & Neuromodulation

107,820

 

116,911

 

(7.8

)%

 

(7.8

)%

Advanced Surgical, Orthopedics & Portable Medical

31,237

 

31,588

 

(1.1

)%

 

(1.1

)%

Total Medical Sales

318,262

 

301,073

 

5.7

%

 

5.4

%

Non-Medical Sales

10,164

 

13,603

 

(25.3

)%

 

(25.3

)%

Total Sales

$

328,426

 

$

314,676

 

4.4

%

 

4.0

%

 

 

 

 

 

 

 

 

Income from continuing operations

$

31,100

 

$

21,366

 

45.6

%

 

23.3

%

Diluted EPS from continuing operations

$

0.94

 

$

0.65

 

44.6

%

 

23.0

%

(a) Organic Growth is a Non-GAAP measure.  Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures and refer to Table C and Table D at the end of this release for a reconciliation of these amounts.

 

Three Months Ended

Non-GAAP(a)

April 3,
2020

 

March 29,
2019

 

Change

 

Organic
Growth(b)

Adjusted EBITDA from continuing operations

$

70,691

 

$

65,660

 

7.7

%

 

5.5

%

Adjusted income from continuing operations

$

41,284

 

$

32,840

 

25.7

%

 

23.3

%

Adjusted diluted EPS from continuing operations

$

1.25

 

$

1.00

 

25.0

%

 

23.0

%

(a) Refer to Tables A and B at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.

(b) Organic Growth for Adjusted EBITDA from continuing operations, Adjusted income from continuing operations, and Adjusted diluted EPS from continuing operations are Non-GAAP measures.  Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures and refer to Table D at the end of this release for a reconciliation of these amounts.

Conference Call Information
The Company will host a conference call on Thursday, May 7, 2020, at 5:00 p.m. EDT / 4:00 p.m. CDT to discuss these results.  The scheduled conference call will be webcast live and is accessible through our website at investor.integer.net or by dialing (833) 236-5762 (U.S.) or (647) 689-4190 (outside U.S.) and the conference ID is 4978959.  The call will be archived on the Company’s website.  An earnings call slide presentation containing supplemental information about the Company’s results will be posted to our website at investor.integer.net prior to the conference call and will be referenced during the conference call.

About Integer®
Integer Holdings Corporation (ITGR) is one of the largest medical device outsource (MDO) manufacturers in the world serving the cardiac, neuromodulation, vascular, portable medical and orthopedics markets. The Company provides innovative, high-quality medical technologies that enhance the lives of patients worldwide. In addition, the Company develops batteries for high-end niche applications in energy, military, and environmental markets. The Company's brands include Greatbatch Medical®, Lake Region MedicalTM and ElectrochemTM. Additional information is available at www.integer.net.

Contact Information
Tony Borowicz
SVP, Strategy, Business Development & Investor Relations
716.759.5809
tony.borowicz@integer.net

Notes Regarding Non-GAAP Financial Information
In addition to our results reported in accordance with generally accepted accounting principles (“GAAP”), we provide  adjusted income, adjusted diluted EPS, earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted EBITDA, adjusted EBITDA margin, and organic growth rates, all from continuing operations.  Adjusted income and adjusted diluted EPS from continuing operations consist of GAAP amounts adjusted for the following to the extent occurring during the period: (i) acquisition and integration related expenses, including fair value adjustments to contingent consideration resulting from acquisitions, (ii) amortization of intangible assets, (iii) facility consolidation, optimization, manufacturing transfer and system integration charges, (iv) asset write-down and disposition charges, (v) charges in connection with corporate realignments or a reduction in force, (vi) certain legal expenses, charges and gains, (vii) unusual or infrequently occurring items, (viii) gain (loss) on equity investments, (ix) extinguishment of debt charges, (x) the income tax provision (benefit) related to these adjustments and (xi) certain tax items that are outside the normal provision for the period.  Adjusted diluted EPS from continuing operations is calculated by dividing adjusted income from continuing operations by diluted weighted average shares outstanding.  EBITDA from continuing operations is calculated by adding back interest expense, GAAP provision (benefit) for income taxes, depreciation and amortization expense, to income from continuing operations, which is the most directly comparable GAAP measure.  Adjusted EBITDA from continuing operations consists of EBITDA from continuing operations plus GAAP stock-based compensation and the same adjustments as listed above except for items (ii), (ix), (x) and (xi).

Adjusted EBITDA margin is adjusted EBITDA as a percentage of sales, all from continuing operations. Organic sales growth is reported sales growth adjusted for the impact of foreign currency and the contribution of acquisitions.  To calculate the impact of foreign currency on sales growth rates, we convert any sale made in a foreign currency by converting current period sales into prior period sales using the exchange rate in effect at that time and then compare the two, negating any effect foreign currency had on our transactional revenue, and exclude the amount of sales acquired/divested during the period from the current/previous period amounts, respectively.

Organic growth rates for adjusted EBITDA from continuing operations, adjusted income from continuing operations and adjusted diluted EPS from continuing operations exclude the impact of foreign currency exchange gains and losses included in other (income) loss, net, and the contribution of acquisitions. Contribution of acquisitions represents results, based on the growth rate being presented, attributable to acquired entities for the first four full quarters plus any partial period since the entities' acquisition date.  After the completion of four full fiscal quarters, results of the acquired entity are treated as organic for current and comparable historical periods.

We believe that the presentation of adjusted income, adjusted diluted EPS, EBITDA, adjusted EBITDA, adjusted EBITDA margin, and organic growth rates, all from continuing operations, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations.  In addition to the performance measures identified above, we believe that leverage ratio provides a meaningful measure of liquidity and a useful basis for assessing our ability to fund our activities, including the financing of acquisitions and debt repayments.  We calculate leverage ratio as total principal amount of debt outstanding less cash and cash equivalents divided by trailing 4 quarters adjusted EBITDA.

Forward-Looking Statements
Some of the statements contained in this press release are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements relating to the impact of the COVID-19 global pandemic; future sales, expenses, and profitability; future development and expected growth of our business and industry; our ability to execute our business model and our business strategy; having available sufficient cash and borrowing capacity to meet working capital, debt service and capital expenditure requirements for the next twelve months; and projected capital spending.  You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or “variations” or the negative of these terms or other comparable terminology. These statements are only predictions.  Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below.

Although it is not possible to create a comprehensive list of all factors that may cause actual results to differ from the results expressed or implied by our forward-looking statements or that may affect our future results, some of these factors include the following: the duration, scope and impact of the COVID-19 pandemic, including government, social, business and other actions taken in response to the pandemic and the effect of the pandemic on our associates, suppliers and customers as well as the global economy; our dependence upon a limited number of customers; pricing pressures that we face from customers; our ability to respond to changes in technology; the intense competition we face and our ability to successfully market our products; our ability to develop new products and expand into new geographic and product markets; our reliance on third party suppliers for raw materials, key products and subcomponents; the potential for harm to our reputation caused by quality problems related to our products; regulatory issues resulting from products complaints, recalls or regulatory audits; the potential of becoming subject to product liability claims; our ability to protect our intellectual property and proprietary rights; our significant amount of outstanding indebtedness and our ability to remain in compliance with financial and other covenants under our senior secured credit facilities; our ability to integrate acquisitions and operate acquired businesses in accordance with expectations; our dependence upon our senior management team and technical personnel; our ability to realize the benefits from cost savings and consolidation initiatives; interruptions in our manufacturing operations; our ability to comply with environmental regulations; our complex international tax profile; our dependence upon our information technology systems and our ability to prevent cyber-attacks and other failures; market, financial and other risks related to our international operations and sales; global economic factors, including currency exchange rates and interest rates; the fact that the healthcare industry is highly regulated and subject to various regulatory changes; the dependence of our energy market-related revenues on the conditions in the oil and natural gas industry; and other risks and uncertainties that arise from time to time and are described in Item 1A “Risk Factors” of our Annual Report on Form 10-K and in our other periodic filings with the SEC. Except as may be required by law, we assume no obligation to update forward-looking statements in this press release whether to reflect changed assumptions, the occurrence of unanticipated events or changes in future operating results, financial conditions or prospects, or otherwise.

 

Condensed Consolidated Statements of Operations - Unaudited

(in thousands except per share data)

 

 

 

 

Three Months Ended

 

April 3,
2020

 

March 29,
2019

Sales

$

328,426

 

 

$

314,676

 

Cost of sales

231,724

 

 

226,066

 

Gross profit

96,702

 

 

88,610

 

Operating expenses:

 

 

 

Selling, general and administrative expenses (SG&A)

36,457

 

 

34,956

 

Research, development and engineering costs (RD&E)

13,241

 

 

11,595

 

Other operating expenses (OOE)

2,928

 

 

2,890

 

Total operating expenses

52,626

 

 

49,441

 

Operating income

44,076

 

 

39,169

 

Interest expense

10,361

 

 

13,830

 

(Gain) loss on equity investments, net

(1,925

)

 

41

 

Other (income) loss, net

(999

)

 

166

 

Income from continuing operations before taxes

36,639

 

 

25,132

 

Provision for income taxes

5,539

 

 

3,766

 

Income from continuing operations

$

31,100

 

 

$

21,366

 

 

 

 

 

Discontinued operations:

 

 

 

Income from discontinued operations before taxes

 

 

386

 

Provision for income taxes

 

 

83

 

Income from discontinued operations

$

 

 

$

303

 

 

 

 

 

Net income

$

31,100

 

 

$

21,669

 

 

 

 

 

Basic earnings per share:

 

 

 

Income from continuing operations

$

0.95

 

 

$

0.66

 

Income from discontinued operations

$

 

 

$

0.01

 

Basic earnings per share

$

0.95

 

 

$

0.67

 

 

 

 

 

Diluted earnings per share:

 

 

 

Income from continuing operations

$

0.94

 

 

$

0.65

 

Income from discontinued operations

$

 

 

$

0.01

 

Diluted earnings per share

$

0.94

 

 

$

0.66

 

 

 

 

 

Weighted average shares outstanding:

 

 

 

Basic

32,807

 

 

32,536

 

Diluted

33,117

 

 

32,980

 


Condensed Consolidated Balance Sheets - Unaudited

(in thousands)

 

 

 

April 3,
2020

 

December 31,
2019

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

37,259

 

 

$

13,535

 

Accounts receivable, net

199,785

 

 

191,985

 

Inventories

170,298

 

 

167,256

 

Contract assets

38,882

 

 

24,767

 

Prepaid expenses and other current assets

14,598

 

 

17,852

 

Total current assets

460,822

 

 

415,395

 

Property, plant and equipment, net

246,378

 

 

246,185

 

Goodwill

839,395

 

 

839,617

 

Other intangible assets, net

766,535

 

 

775,784

 

Deferred income taxes

5,045

 

 

4,438

 

Operating lease assets

49,039

 

 

42,379

 

Other long-term assets

30,813

 

 

29,295

 

Total assets

$

2,398,027

 

 

$

2,353,093

 

LIABILITIES AND STOCKHOLDERS’ EQUITY

 

 

 

Current liabilities:

 

 

 

Current portion of long-term debt

$

37,500

 

 

$

37,500

 

Accounts payable

79,138

 

 

64,975

 

Income taxes payable

7,564

 

 

3,023

 

Current portion of lease liabilities

7,951

 

 

7,507

 

Accrued expenses and other current liabilities

53,976

 

 

66,073

 

Total current liabilities

186,129

 

 

179,078

 

Long-term debt

793,829

 

 

777,272

 

Deferred income taxes

185,814

 

 

187,978

 

Operating lease liabilities

42,482

 

 

37,114

 

Other long-term liabilities

25,572

 

 

19,163

 

Total liabilities

1,233,826

 

 

1,200,605

 

Stockholders’ equity:

 

 

 

Common stock

33

 

 

33

 

Additional paid-in capital

694,746

 

 

701,018

 

Treasury stock

(1,263

)

 

(8,809

)

Retained earnings

471,358

 

 

440,258

 

Accumulated other comprehensive income (loss)

(673

)

 

19,988

 

Total stockholders’ equity

1,164,201

 

 

1,152,488

 

Total liabilities and stockholders’ equity

$

2,398,027

 

 

$

2,353,093

 

 

Condensed Consolidated Statements of Cash Flows(a) - Unaudited

(in thousands)

 

Three Months Ended

 

April 3,

 

March 29,

 

2020

 

2019

Cash flows from operating activities:

 

 

 

 

 

 

 

Net income

$

31,100

 

 

$

21,669

 

Adjustments to reconcile net income to net cash provided by operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

19,494

 

 

 

19,658

 

Debt related charges included in interest expense

 

1,023

 

 

 

1,774

 

Stock-based compensation

 

1,738

 

 

 

2,713

 

Non-cash charges related to customer bankruptcy

 

628

 

 

 

 

Non-cash lease expense

 

1,930

 

 

 

1,864

 

Non-cash (gain) loss on equity investments

 

(1,925

)

 

 

41

 

Other non-cash gains

 

(1,085

)

 

 

(1,075

)

Deferred income taxes

 

61

 

 

 

96

 

Changes in operating assets and liabilities, net of acquisition:

 

 

 

 

 

 

 

Accounts receivable

 

(8,165

)

 

 

(30,924

)

Inventories

 

(4,365

)

 

 

8,612

 

Prepaid expenses and other assets

 

(13,350

)

 

 

(14,266

)

Accounts payable

 

18,458

 

 

 

15,411

 

Accrued expenses and other liabilities

 

(18,108

)

 

 

(15,894

)

Income taxes payable

 

4,963

 

 

 

1,555

 

Net cash provided by operating activities

 

32,397

 

 

 

11,234

 

Cash flows from investing activities:

 

 

 

 

 

 

 

Acquisition of property, plant and equipment

 

(14,925

)

 

 

(7,447

)

Purchase of intangible asset

 

(3,500

)

 

 

 

Proceeds from sale of property, plant and equipment

 

52

 

 

 

2

 

Purchase of equity investments

 

 

 

 

(42

)

Acquisitions, net

 

(5,219

)

 

 

 

Net cash used in investing activities

 

(23,592

)

 

 

(7,487

)

Cash flows from financing activities:

 

 

 

 

 

 

 

Principal payments of long-term debt

 

(9,375

)

 

 

(30,375

)

Proceeds from senior secured revolving line of credit

 

25,000

 

 

 

15,000

 

Proceeds from the exercise of stock options

 

2,201

 

 

 

1,338

 

Tax withholdings related to net share settlements of restricted stock unit awards

 

(2,664

)

 

 

(2,123

)

Net cash provided by (used in) financing activities

 

15,162

 

 

 

(16,160

)

Effect of foreign currency exchange rates on cash and cash equivalents

 

(243

)

 

 

382

 

Net increase (decrease) in cash and cash equivalents

 

23,724

 

 

 

(12,031

)

Cash and cash equivalents, beginning of period

 

13,535

 

 

 

25,569

 

Cash and cash equivalents, end of period

$

37,259

 

 

$

13,538

 

 

 

 

 

 

 

 

 

(a)  Condensed Consolidated Statements of Cash Flows - Unaudited includes cash flows related to discontinued operations.

 

 

 

Reconciliations of Non-GAAP Measures from Continuing Operations

Table A: Income from Continuing Operations and Diluted EPS Reconciliations
(in thousands except per share amounts)

 

Three Months Ended

 

April 3, 2020

 

March 29, 2019

 

Pre-Tax

 

Net of
Tax

 

Per
Diluted
Share

 

Pre-Tax

 

Net of
Tax

 

Per
Diluted
Share

Income from continuing operations (GAAP)

$

36,639

 

 

$

31,100

 

 

$

0.94

 

 

$

25,132

 

 

$

21,366

 

 

$

0.65

 

Adjustments(a):

 

 

 

 

 

 

 

 

 

 

 

Amortization of intangibles

10,444

 

 

8,254

 

 

0.25

 

 

9,854

 

 

7,796

 

 

0.24

 

Certain legal expenses (SG&A)

602

 

 

475

 

 

0.01

 

 

1,396

 

 

1,103

 

 

0.03

 

Other operating expenses (OOE)(b)

2,928

 

 

2,301

 

 

0.07

 

 

2,890

 

 

2,217

 

 

0.07

 

(Gain) loss on equity investments, net

(1,925

)

 

(1,521

)

 

(0.05

)

 

41

 

 

32

 

 

 

Loss on extinguishment of debt

 

 

 

 

 

 

412

 

 

326

 

 

0.01

 

Customer bankruptcy(c)

854

 

 

675

 

 

0.02

 

 

 

 

 

 

 

Adjusted income from continuing operations (Non-GAAP)

$

49,542

 

 

$

41,284

 

 

$

1.25

 

 

$

39,725

 

 

$

32,840

 

 

$

1.00

 

 

 

 

 

 

 

 

 

 

 

 

 

Diluted weighted average shares for adjusted EPS

 

 

33,117

 

 

 

 

 

 

32,980

 

 

 

(a) The difference between pre-tax and net of tax amounts is the estimated tax impact related to the respective adjustment.  Net of tax amounts are computed using a 21% U.S. tax rate, and the statutory tax rates applicable in foreign tax jurisdictions, as adjusted for the existence of net operating losses (“NOLs”).  Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.

(b) Other operating expenses includes acquisition and integration related expenses, facility consolidation, optimization, manufacturing transfer and system integration charges, asset write-down and disposition charges, charges in connection with corporate realignments or a reduction in force, unusual or infrequently occurring items.

(c) In November 2019, one of our customers, Nuvectra Corporation, filed a voluntary Chapter 11 bankruptcy petition (the “Customer Bankruptcy”).  During the first quarter of 2020, we incurred costs and recorded charges associated with the Customer Bankruptcy, primarily consisting of an $0.8 million charge related to inventory recorded in cost of sales in our condensed consolidated statement of operations.

Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures.

 

 

Table B: EBITDA Reconciliations

 

(in thousands)

 

 

Three Months Ended

 

April 3,
2020

 

March 29,
2019

Income from continuing operations (GAAP)

$

31,100

 

 

$

21,366

 

 

 

 

 

Interest expense

10,361

 

 

13,830

 

Provision for income taxes

5,539

 

 

3,766

 

Depreciation

9,050

 

 

9,804

 

Amortization of intangibles (excluding OOE)

10,444

 

 

9,854

 

EBITDA from continuing operations (Non-GAAP)

66,494

 

 

58,620

 

Stock-based compensation (excluding OOE)

1,738

 

 

2,713

 

Certain legal expenses

602

 

 

1,396

 

Other operating expenses (OOE)

2,928

 

 

2,890

 

(Gain) loss on equity investments, net

(1,925

)

 

41

 

Customer bankruptcy

854

 

 

 

Adjusted EBITDA from continuing operations (Non-GAAP)

$

70,691

 

 

$

65,660

 

 

 

 

 

Total Sales

$

328,426

 

 

$

314,676

 

 

 

 

 

Adjusted EBITDA margin

21.5

%

 

20.9

%


 

Table C: Organic Sales from Continuing Operations Growth Rate Reconciliation (% Change)

 

 

GAAP
Reported
Growth

 

Impact of
Acquisitions
and Foreign
Currency(a)

 

Non-GAAP
Organic
Growth

QTD Change (1Q 2020 vs. 1Q 2019)

 

 

 

 

 

Medical Sales

 

 

 

 

 

Cardio & Vascular

17.5%

 

(0.7)%

 

16.8%

Cardiac & Neuromodulation

(7.8)%

 

 

(7.8)%

Advanced Surgical, Orthopedics & Portable Medical

(1.1)%

 

—%

 

(1.1)%

Total Medical Sales

5.7%

 

(0.3)%

 

5.4%

Non-Medical Sales

(25.3)%

 

 

(25.3)%

Total Sales

4.4%

 

(0.4)%

 

4.0%

(a) First quarter 2020 sales have been adjusted to exclude the contribution of business acquisitions and foreign currency exchange rate fluctuations.


 

Table D: Non-GAAP Organic Growth Rate Reconciliation (% Change)

 

 

GAAP
Reported
Growth(a)

 

Impact of
Non-GAAP
Adjustments(b)

 

Impact of
Acquisitions
and Foreign
Currency(c)

 

Non-GAAP
Organic
Growth

QTD Change (1Q 2020 vs. 1Q 2019)

 

 

 

 

 

 

 

EBITDA from continuing operations

13.4%

 

(5.7)%

 

(2.2)%

 

5.5%

Income from continuing operations

45.6%

 

(19.9)%

 

(2.4)%

 

23.3%

Diluted EPS from continuing operations

44.6%

 

(19.6)%

 

(2.0)%

 

23.0%

(a) EBITDA from continuing operations is a non-GAAP financial measure.  See Table B for a reconciliation to the most comparable GAAP measure.

(b) Represents the impact to our growth rate from our Non-GAAP adjustments. See Tables A and B for further detail on these items.

(c) Represents the impact to our growth rate due to changes in foreign currency exchange rates realized in income and reported in other (income) loss, net in the consolidated statements of operations, and the adjustment to exclude the contribution of acquisitions.